Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
MONROVIA, Calif. , Dec. 3, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1
View HTML
Toggle Summary Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference
MONROVIA, Calif. , Nov. 20, 2018 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors
MONROVIA, Calif. , Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G.
View HTML
Toggle Summary Xencor Reports Third Quarter 2018 Financial Results
- Initial Data from Phase 1 Dose-Escalation Study of XmAb®14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) by Early 2019 - - Expect to Initiate Phase 1 Studies for Bispecific Tumor
View HTML
Toggle Summary Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
MONROVIA, Calif. , Nov. 1, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1
View HTML
Toggle Summary Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release third
View HTML
Toggle Summary Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting
- Positive trend in primary endpoint; proportion of efficacy-evaluable patients who did not experience loss of improvement (LOI) by Day 225 did not meet statistical significance (XmAb®5871 42% vs. placebo 28.6%, p = 0.18) - Met secondary endpoint of time to LOI; risk of LOI reduced by 47% for
View HTML
Toggle Summary Xencor to Participate in Upcoming Investor Conferences
MONROVIA, Calif. , Sept. 25, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Toggle Summary Xencor Reports Second Quarter 2018 Financial Results
- Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb®20717 in Advanced Solid Tumors - - Expect to Announce Topline Data from Phase 2 Trial of XmAb®5871 in Systemic Lupus Erythematosus (SLE) and Initial Data from Phase 1 Trial of XmAb®14045
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Aug. 1, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Xencor © Copyright 2018